Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFINE CCS: Ticagrelor vs. Rivaroxaban in Chronic Coronary Syndrome
NCT05116995Phase 4Unknown
- Sponsor
- Nova Scotia Health
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ticagrelor, rivaroxaban in Chronic Coronary Syndrome (CCS), myocardial infarction (MI), sponsored by Nova Scotia Health. Status: unknown.
02
Drugs
ticagrelorrivaroxaban
03
Conditions
Chronic Coronary Syndrome (CCS)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT05116995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116995.